Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Articles|November 16, 2026

FDA Approves Roche's Obinutuzumab (Gazyva) for Membranous Nephropathy

Listen
0:00 / 0:00

Key Takeaways

  • FDA authorized obinutuzumab to induce proteinuria remission in adults with primary membranous nephropathy at risk of progression, representing the first approved treatment specifically for pMN.
  • In MAJESTY (N=142), complete remission at week 104 was 36.1% with obinutuzumab versus 5.7% with tacrolimus (adjusted difference 31.1%; p<.001).
SHOW MORE

Obinutuzumab produced complete proteinuria remission in 36.1% of primary membranous nephropathy patients at 2 years vs 5.7% with tacrolimus.

FDA has approved obinutuzumab (Gazyva) to induce remission of proteinuria in adults with primary membranous nephropathy (pMN) who are at risk of disease progression, Roche announced on November 16, 2026.¹ According to the company, it is the first FDA-approved therapy for pMN, a chronic autoimmune kidney disease. Obinutuzumab had previously received breakthrough therapy designation for this use, and FDA granted the supplemental application priority review in July 2026.¹

Key facts

  • Drug: obinutuzumab (Gazyva; Roche)
  • Class: Type II anti-CD20 humanized monoclonal antibody (glycoengineered Fc)
  • Indication: Adults with pMN at risk of disease progression, to induce remission of proteinuria
  • Trial: MAJESTY (NCT04629248); phase 3, randomized, open-label, n=142
  • Primary end point met: Complete remission at week 104, 36.1% vs 5.7% with tacrolimus
  • Secondary end points: Overall remission 50% vs 12.9%; complete remission at week 76, 36.1% vs 8.6%
  • Safety: Consistent with known profile; no new safety signals
  • Approval: FDA, announced November 16, 2026; first approved therapy for pMN
  • Prior designation: Breakthrough therapy
  • Other kidney approvals: Lupus nephritis; idiopathic nephrotic syndrome (US)

“The FDA approval of Gazyva/Gazyvaro represents an important step forward for people living with primary membranous nephropathy, where targeting B cells addresses a critical underlying driver of disease,” said Levi Garraway, MD, PhD, Roche's chief medical officer and head of global product development, in a company press release.¹

What did the MAJESTY trial show?

The approval is based on the phase 3 MAJESTY study (NCT04629248). This randomized, open-label, multicenter trial enrolled 142 adults with pMN and randomized them 1:1 to obinutuzumab or tacrolimus.¹,² The trial met its primary end point, in which 36.1% of patients receiving obinutuzumab achieved complete remission of proteinuria at 2 years (week 104) vs 5.7% of those receiving tacrolimus (adjusted difference, 31.1%; 95% confidence interval [CI]: 18.2 to 44.0; p<.001).¹,³

Obinutuzumab was also shown to be superior to tacrolimus on key secondary end points.¹ Overall remission (complete or partial) at week 104 was 50% vs 12.9% (adjusted difference, 37.8%; 95% CI: 23.9 to 51.8; p<.001). Complete remission at week 76 was 36.1% vs 8.6% (adjusted difference, 27.4%; 95% CI: 13.4 to 39.8; p<.001).¹ The results were a late-breaking oral presentation at the 63rd European Renal Association Congress in June 2026 and were published in the New England Journal of Medicine.¹,³

According to Roche, safety in MAJESTY was in line with the established profile of obinutuzumab, and no new safety signals were identified.¹

How does obinutuzumab work?

Obinutuzumab is a humanized monoclonal antibody with 2 engineered features. Its type II anti-CD20 region is designed to kill B cells directly, and its glycoengineered Fc region is designed for higher binding affinity and increased antibody-dependent cellular cytotoxicity.¹ CD20 is a protein found on certain types of B cells. In pMN, the immune system attacks the glomeruli, the kidney's filtering units. This causes protein to leak into the urine and can gradually reduce kidney function.¹

Why does this approval matter?

According to Roche, pMN has an estimated incidence of 1.2 per 100,000 people in the United States per year, and up to 30% of untreated patients progress to kidney failure within 10 years.¹ Complete remission is important to help maintain kidney function and delay or prevent serious complications.¹

“The first FDA approval of a treatment specifically for this condition is a milestone, finally giving patients and clinicians more treatment options,” said Marc Hurlbert, PhD, CEO of the National Kidney Foundation, in the release.¹

This is the third FDA approval of obinutuzumab in immune-mediated kidney diseases, following approvals in idiopathic nephrotic syndrome and lupus nephritis.¹ FDA is also reviewing obinutuzumab for adults with systemic lupus erythematosus, with a decision expected by December 2026. MAJESTY data are being submitted to other health authorities, including the European Medicines Agency.¹

What are the limitations?

MAJESTY was open-label, so patients and investigators knew which treatment was assigned. The comparator was tacrolimus, and the release does not report comparisons with other therapies. The release does not give adverse event rates, discontinuation data, or label warnings. It also does not define the “at risk of disease progression” population covered by the approved indication. Longer-term outcomes, including kidney failure, were not reported.

References

  1. Roche. Roche's Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy. Press release. Published November 16, 2026. Accessed November 16, 2026. https://www.roche.com/media/releases/med-cor-2026-11-16
  2. A study evaluating the efficacy and safety of obinutuzumab in participants with primary membranous nephropathy (MAJESTY). ClinicalTrials.gov; NCT04629248. Updated October 1, 2026. Accessed November 16, 2026. https://clinicaltrials.gov/study/NCT04629248
  3. Fervenza FC, Hou FF, Hao CM, et al. Obinutuzumab or tacrolimus in primary membranous nephropathy. N Engl J Med. 2026;395(10):959-971. doi:10.1056/NEJMoa2602678

Related to this article